Here are the 10-Q quarterly reports from Nexentis Technologies Inc. (NXTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NXTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTS filings page.
Nexentis Technologies Inc., a Nevada-based company with oncology (MitoCareX) and renewable energy (NITO/solar JV) activities, reported a net loss of $17.7 million for the six months ended June 30, 2026, compared with $5.8 million a year earlier. Results include a $6.3 million non-cash goodwill impairment on the MitoCareX reporting unit and financing expenses of $8.9 million, largely linked to fair value changes in warrant and credit facility liabilities.
Total assets were $18.7 million, with cash, cash equivalents and restricted cash of $7.7 million. Total liabilities rose to $16.9 million, driven by warrant-related liabilities and contingent considerations, leaving total stockholders’ equity at $1.8 million. The company has an accumulated deficit of about $56.3 million and states there is substantial doubt about its ability to continue as a going concern, expecting continued losses and negative operating cash flows.
To fund operations, Nexentis raised capital via a standby equity purchase, June 2026 registered direct offerings and related PIPE warrants, and expanded a credit facility with Pure Capital that includes a large warrant position accounted for as a liability. It also completed a 1-for-7 reverse stock split and deconsolidated its former Save Foods business, recording an $0.9 million gain in discontinued operations and receiving Voice Assist shares now measured at fair value.
Nexentis Technologies Inc. reported a much larger quarterly loss as it reshaped its business around oncology biotech and renewable energy projects. For the three months ended March 31, 2026, total assets were $16.4M and cash and cash equivalents were $4.3M.
The company posted an operating loss of $8.2M and a net loss of $6.6M, or $10.74 per basic share, driven mainly by a non‑cash goodwill impairment of $6.3M related to the MitoCareX oncology unit and higher share‑based compensation.
Nexentis closed the sale of its former Save Foods business, recognizing an $0.9M gain in discontinued operations, and received Voice Assist shares now valued at $1.7M. Management disclosed substantial doubt about the company’s ability to continue as a going concern beyond early 2027 without additional financing, despite having $6.5M of working capital and ongoing access to equity facilities.